Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 1065793 10.3389/fphar.2022.1065793 Pharmacology Mini Review Nanotechnology in cervical cancer immunotherapy: Therapeutic vaccines and adoptive cell therapy Zhou et al. 10.3389/fphar.2022.1065793 Zhou Xuyan 1 † Lian Haiying 1 † Li Hongpeng 1 Fan Meiling 2 * Xu Wei 1 * Jin Ye 1 * 1 School of Pharmacy, Changchun University of Chinese Medicine, Changchun, China 2 Gynecology Department, Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China

Edited by: Zhaogang Yang, Jilin University, China

Reviewed by: Shuai Wang, University of Texas Southwestern Medical Center, United States

Yang Xing, University of Texas Southwestern Medical Center, United States

Xintao Tu, University of Texas Southwestern Medical Center, United States

 *Correspondence: Meiling Fan, fanmeiling1982@163.com; Wei Xu, 1272349594@qq.com; Ye Jin, jy_ccucm@163.com

These authors have contributed equally to this work and share first authorship

This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology

 16 12 2022 2022 13 1065793 10 10 2022 01 12 2022 Copyright © 2022 Zhou, Lian, Li, Fan, Xu and Jin. 2022 Zhou, Lian, Li, Fan, Xu and Jin

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Immunotherapy is an emerging method for the treatment of cervical cancer and is more effective than surgery and radiotherapy, especially for recurrent cervical cancer. However, immunotherapy is limited by adverse effects in clinical practice. In recent years, nanotechnology has been widely used for tumor diagnosis, drug delivery, and targeted therapy. In the setting of cervical cancer, nanotechnology can be used to actively or passively target immunotherapeutic agents to tumor sites, thereby enhancing local drug delivery, reducing drug adverse effects, achieving immunomodulation, improving the tumor immune microenvironment, and optimizing treatment efficacy. In this review, we highlight the current status of therapeutic vaccines and adoptive cell therapy in cervical cancer immunotherapy, as well as the application of lipid carriers, polymeric nanoparticles, inorganic nanoparticles, and exosomes in this context.

 cervical cancer nanotechnology immunotherapy therapeutic vaccine adoptive cell therapy nanocarriers Introduction

Cervical cancer is caused by the growth of abnormal cells spreading to other parts of the body. It is one of the most common female reproductive malignancies (Bedell et al., 2020). Globally in 2020, there were 604,000 new cases of cervical cancer and 342,000 deaths. Cervical cancer is the fourth-leading cause of cancer incidence and mortality among women worldwide after breast cancer, lung cancer, and colon cancer (World Health Organization, 2022). Cervical cancer has a high incidence and tends to be younger. Therefore, cervical cancer has become a substantial public health concern (Ibrahim Khalil et al., 2022).

Smoking, poor hygiene, early initiation of sexual intercourse, and having multiple sexual partners are risk factors for cervical cancer (Small et al., 2017). The main cause of cervical cancer is persistent high-risk human papillomavirus (HPV) infection. E6 and E7 are HPV oncoproteins that interact with the tumor suppressors p53 and retinoblastoma protein (pRb), respectively. Activation of apoptotic pathways is disrupted by these interactions, which subsequently promote cell proliferation and ultimately increase progression of HPV-associated malignancies (Jee et al., 2021). At present, more than 200 HPV subtypes have been identified that primarily infect cells in mucous membranes and the epidermis (Perri et al., 2003). These subtypes can be classified into high-risk and low-risk types depending on whether or not they promote the development of malignant lesions. Low-risk HPV types do not cause cancer but can cause genital warts. In contrast, only 12 high-risk HPV types are oncogenic (Dell et al., 2008; Aranda-Rivera et al., 2021). The most prevalent high-risk HPV type is HPV 16, which is associated with approximately 50% of cervical cancer cases, followed by HPV 18 and HPV 31 (Stuebs et al., 2021).

Depending on the diagnosis, clinicopathological features, and other risk factors of the disease stage, surgery or a combination of chemotherapy and radiotherapy is included as first-line therapy treatment (Cohen et al., 2019). Due to the expansion of early detection methods and enhanced efficacy of surgery and radiotherapy, the prognoses of patients with early cervical cancer has been significantly improved. However, most conventional treatments can only achieve therapeutic effects on local solid tumors. The survival rates of patients with advanced, recurrent, or metastatic cervical cancer are still poor (Lee et al., 2019; Liontos et al., 2019). Indeed, the 5-year survival rate of patients with cervical cancer is 60%–70% in countries with high human development index (HDI). In comparison, the survival rate drops to less than 20% in countries with low HDI (Wakeham and Kavanagh, 2014). Most antineoplastic drugs have severe side effects, limiting their maximum tolerated dose. Together with the development of drug resistance, this factor leads to decreased therapeutic efficacy (Ghalkhani et al., 2022). Therefore, it is crucial that more effective treatments should be developed. Immunotherapy can eliminate tumors and prevent tumor recurrence by eliciting long-term effects on immune memory (Chen et al., 2022).

However, in the setting of cervical cancer, immunotherapy is still associated with clinical challenges such as low immunogenicity, inefficient targeting, and immunotoxicity (Song et al., 2015, 20). With the rapid development of nanotechnology, clinical diagnoses and treatments for cervical cancer have greatly improved. For example, nanotechnology-mediated delivery of drugs can increase drug solubility, control drug release rates in vivo, and improve drug stability. Also, nanotechnology-mediated delivery systems have the ability to deliver one or more treatments (e.g., chemotherapeutic drugs and/or immunotherapeutic agents) to the lesion site. Additionally, combining nanotechnology with imaging modalities can facilitate visualization of the drug delivery process (Irvine and Dane, 2020; Martin et al., 2020). Furthermore, mesoporous silica and gold nanoparticles can enhance the sensitivity of clinical cervical cancer diagnoses and enable early detection and timely treatment (Palantavida et al., 2013; Yin et al., 2020). In this review, we discuss the utility of therapeutic vaccines and adoptive cell therapy in cervical cancer immunotherapy, as well as summarize the application of nanotechnology in this context.

 Immunotherapy and cervical cancer

Immunotherapy leverages immunological principles and methods to activate and enhance the body’s immune system. Immunotherapy can enhance the ability of immune system to recognize, attack, and neutralize tumor cells, thereby inhibiting tumor growth (Duan et al., 2019; Zhang et al., 2022). The mechanisms underlying therapeutic vaccines and adoptive cell therapy are shown in Figure 1.

The mechanisms of therapeutic vaccines and adoptive cell therapy for cervical cancer.

The ideal antigens for cervical cancer therapeutic vaccines are the E6 and E7 viral oncoproteins, which are constitutively expressed by HPV-infected host cells (Miles et al., 2017). Following exposure to co-stimulatory molecules, antigen-presenting cells (APCs) can uptake pathogens and present pathogenic peptides on their surfaces, which can then be recognized by the major histocompatibility complex (MHC) (Purcell et al., 2007; Stark et al., 2019). Live-vector vaccines, such as the bacterial vectors Listeria monocytogenes (Lm), Lactococcus lactis, Lactobacillus plantarum, and Lactobacillus casei are highly immunogenic (Bermúdez-Humarán et al., 2004; Cortes-Perez et al., 2005; Sewell et al., 2008). ADXS11-001 is a live attenuated Lm vaccine that generates an immune response against the HPV 16 E7 oncoprotein. Preliminary results from phase III clinical trials have demonstrated the efficacy of this vaccine against recurrent or persistent cervical cancer (Vonsky et al., 2019). The currently available viral vaccines that target E6 and E7 antigens include adenovirus, alphavirus, Venezuelan equine encephalitis virus (VEER), and cowpox virus, among others (Liu et al., 2000; Cassetti et al., 2004; Hsieh, 2004; Gomez-Gutierrez et al., 2007). For example, Cassetti et al. (Cassetti et al., 2004) assembled HPV 16 E6/E7 genes into a VEER vector via point mutations in order to treat an HPV 16-related mouse tumor model. This study showed that a cytotoxic T lymphocyte (CTL) response against E7 was induced, resulting in tumor regression.

Peptide/protein-based vaccines have the following characteristics: easy production, favorable safety profiles, and storage stability (Vonsky et al., 2019). Phase II clinical trials of the SGN-00101 vaccine (composed of HPV 16 E7 and Mycobacterium bovis heat shock protein) have shown that it can induce the regression of grade II and III cervical intraepithelial neoplasia (Roman et al., 2007). Unlike peptide-based vaccines, protein-based vaccines contain all antigenic epitopes of E6 and E7 and are not restricted by MHC class I. However, both vaccines exhibit low immunogenicity and poor stability in vivo. Lipids or other adjuvants should be added to enhance their immune efficacy (Menderes et al., 2016; Smalley Rumfield et al., 2020).

Nucleic acid-based vaccines can be classified as DNA or RNA vaccines. The vaccines inhibit carcinogenesis by maintaining immunogenicity (e.g., by mutating or recombining oncogenes) (Choi et al., 2020; Turinetto et al., 2022). However, the vaccines containing intact E6/E7 gene fragments carry the risk of cell transformation. Specific human leukocyte antigen epitopes can be expressed by mutating the p53/pRB binding site in E6/E7 or by changing the gene sequence, but does not produce antigen protein to circumvent this hazard (Öhlschläger et al., 2006; Brinkman et al., 2007). Nucleic acid vaccines are not only stable and easily produced, but also can be administered repeatedly. However, they are less immunogenic and diffuse, and show low immunogenicity. Adjuvants, combination treatments, and multiple vaccination methods should be needed to enhance immunogenicity (Menderes et al., 2016).

Unlike the other three vaccines, dendritic cell (DC)-based vaccines are the only vaccines that can activate naive T cells. In vitro, DCs can be sensitized with viral peptides, DNA, or RNA. Subsequently, HPV antigens are loaded in a vaccine and inject into the body to increase the efficacy of antigen presentation (Kumbhari et al., 2020; Fu et al., 2022). DC-based vaccines can also be used as delivery adjuvants to enhance T cell-mediated immunity in HPV-associated lesions. However, due to their complexity and costly production, these vaccines cannot be produced on large scale (Zeng et al., 2018).

Adoptive cell therapy (ACT) involves the amplification of highly effective tumor-reactive cells collected from patients through in vitro activation or genetic engineering transformation. ACT is a form of personalized medicine that can amplify the immunity of many cell types, including chimeric antigen receptor-natural killer cells (CAR-NKs), cytokine-induced killer cells (CIKs), tumor-infiltrating lymphocytes (TILs), T cell receptor-T cells (TCR-Ts), and chimeric antigen receptor-T cells (CAR-Ts) (Ye et al., 2017; Yeh et al., 2017; Rohaan et al., 2019). The preparation of T cell receptors are complicated in vitro, which are required presentation by the MHC system. So it is difficult to produce on a large scale (Dai et al., 2019). In contrast, CAR-NKs can kill a broad spectrum of tumor cell types efficiently and without pre-sensitization. Studies have shown that increasing proportion of NKs in the external environment of cervical cells can ablate HPV colonization and suppress infection in tissues, thereby preventing cervical intraepithelial neoplasia from progressing (Lucena et al., 2016).

 Application of nanotechnology in immunotherapy of cervical cancer

Nanotechnology can be used for passive targeting systems because of the enhanced permeability and retention (EPR) effect. In addition, it can enhance the ability of active targeting via surface modification of targeted molecules. Applying nanotechnology enables drugs, antibodies, and immunomodulators to be enriched at the tumor site (Shi and Lammers, 2019; Liu et al., 2021). Subsequently, it reverses immunosuppression in the tumor microenvironment (TME) and activates tumor-specific cytotoxic T cells, thereby improving the efficacy of immunotherapy (Figure 2) (Zhang et al., 2012; Batty et al., 2019). Currently, nanotechnology carriers commonly used for cervical cancer immunotherapy include lipid carriers, polymeric nanoparticles, inorganic nanoparticles, and exosomes. The advantages and limitations of these methods are shown in Table 1.

Nanotechnology-mediated immunotherapy for cervical cancer.

Advantages and limitations of nanotechnology.

Nanotechnology Advantages Limitations References
Lipid-based nanocarriers PEGylated liposome Improve bioavailability Low cellular uptake (Ishida et al., 2003; Mishra et al., 2004)
Biodegradability Accelerated blood clearance phenomenon
Biocompatibility
Tween 80 modified liposomes High physical stability Easy to hemolysis phenomenon (Thumrongsiri et al., 2022)
Enhanced blood-brain barrier permeability Only suitable for intramuscular injection
Lipid Nanoparticles High encapsulation efficiency Difficult to achieve industrial production (Yang et al., 2013)
Improve bioavailability
High physical stability
Biocompatibility
Polymeric nanoparticles PLGA nanoparticles Biocompatibility Low drug loading (Pandita et al., 2015)
Enhance controlled and prolonged effects of drug release
PAMAM nanoparticles High transfection efficiency Existence of cytotoxicity (Choi et al., 2004; Li et al., 2021)
Proton sponge effect
Inorganic nanomaterials AuNPs High physical stability Toxic effect on the biological system (Artiga et al., 2019)
Ultra-small size, large surface area-to-volume ratio and high reactivity Low permeability
Easy surface modification
Mesoporous silica nanoparticles Biocompatibility Uncertainty between particle size and toxicity (Shahabi et al., 2015)
Large surface area-to-volume ratio
Porous structure
Exosomes Genetic engineering modified exosomes Biocompatibility The drug loading process was not controllable (Stremersch et al., 2016)
High biological permeability Existence of cytotoxicity
High targeting
Chemically modified exosomes Simple preparation Functional proteins that may damage membrane surface (Haney et al., 2015)
Controllable process
Lipid-based nanocarriers

Lipid-based nanocarriers are safe and exhibit good biocompatibility. Liposomes are closed, spherical vesicles with a bilayer membrane structure, which are consisted of natural phospholipids (soy phospholipids and lecithin), synthetic phospholipids, or cholesterol (Luiza Ribeiro de Souza et al., 2012). Liposomes can be prepared via the film dispersion, reverse evaporation, chemical gradient, hot-melt, and solvent injection methods. Depending on the preparation technique, single unilamellar vesicles (SUVs), large unilamellar vesicles (LUVs), or multivesicular liposomes (MLVs) can be obtained. The particle size of liposomes is typically ranging 20 nm to a few microns (Al-Jamal et al., 2008; Filipczak et al., 2020). Because of the amphipathic nature of liposomes, water-soluble and lipid-soluble components (e.g., chemotherapeutic drugs, plant extracts, and immune cytokines) can be encapsulated in liposomes. Meanwhile, specific ligands of tumor cell receptors are loaded onto the liposome surfaces in order to improve targeting ability (Filipczak et al., 2020). For example, Chen et al. (Chen and Huang, 2008) developed an improved liposome N-[1-(2,3-Dioleoyloxy) propyl]-N,N,N-trimethylammonium chloride (DOTAP)/E7 lipopeptide vaccine to treat HPV-positive tumors. Compared to natural E7, this vaccine reduced the amount of antigen required to inhibit tumor growth and improved the production of functional CTL responses. Additionally, Karimi et al. (Karimi et al., 2020) combined an late HPV capsid protein (L1)/E6/E7 recombinant gene with Archaeosomes to produce an Archaeosome-L1/E6/E7 vaccine for in vivo evaluation. They found that Archaeosomes resulted in an approximately 3-fold increase in apoptosis levels compared to L1/E6/E7 recombinant gene. It also promoted immune responses to DNA vaccines and exhibited inhibitory activity on tumor cells.

Lipid nanoparticles contain natural or synthetic solid lipids, liquid lipids, and surfactant carrier molecules. Drugs are adsorbed or encapsulated in the lipid core to form particles of 50–1,000 nm in size, which in turn can be prepared by extrusion, ultrasonic, or homogenization methods (Sheoran et al., 2022). Due to the use of electroporation during the transfer of CAR-encoding mRNA into T cells, the integrity CAR-T plasma membrane were compromised, which reduces the next gene expression (Guevara et al., 2020). Patel et al. (2022) developed ionizable lipid nanoparticles to deliver CAR-encoding mRNA into T cells, producing functional CAR-T cells with enhanced tumoricidal activity. The core cavity is more suited to the encapsulation of oligonucleotide drugs, whereas other lipid carriers are more suitable for small molecule inhibitors or lipids. For example, Kranz et al. (2016) found that using lipid carriers such as 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, [1-(2,3-dioleyloxy) propyl]-N,N,N-trimethylammonium chloride, and cholesterol. The uptake and expression of different macrophage populations in lymphoid organs can be enhanced by modulating the negative net charge of the nanoparticles.

 Polymeric nanoparticles

Polymeric nanoparticles are artificial spherical nanoparticles that generally range from 10 to 500 nm in size. They can be prepared by numerous methods including emulsification, aggregation, coacervation, and the supercritical antisolvent technique, among others (Ali, 2020). Polymeric nanoparticles have different classifications according to their structural and functional properties, such as number of polymeric monomers can be classified as unimolecular and multimolecular. Block polymers can be classified as single- and composite-component polymers. Also, most polymeric materials have large molecular weights (Castro et al., 2022). During the formation of nanoparticles, hydrophobic drugs can be encapsulated in the inner core thereby protecting them in the systemic circulation (Kim et al., 2016). Moreover, the hydrophilic shells of polymeric nanoparticles can be modified with active targeting ligands, which can aggregate drugs at tumor sites and improve the therapeutic potentials of chemotherapeutic drugs (Ke et al., 2014). Polymeric materials are characterized by good biodegradability and biocompatibility. Such as polylactic acid, poly (D,L-lactide-co-glycolic acid) (PLGA), and polyglutamic acid which have been extensively investigated for cancer prevention and immunotherapy (Pan et al., 2013; Sadr et al., 2018). For example, co-delivery of an HPV 16 E7 DNA vaccine with interleukin-12 (IL-12) using chitosan increased DNA vaccine E7-specific lymphocyte proliferation and CTL activity (Tahamtan et al., 2018). Moreover, the combined action of chitosan and IL-2 increased HPV 16 L1 antibody titers and mucosal protection (Ma et al., 2015). Additionally, Nagapoosanam et al. (Nagapoosanam et al., 2019) loaded targeted hTERT and siRNA onto PLGA nanoparticles. The nanocarriers enabled the stable release of siRNA for 72 h and significantly accelerated HeLa cell apoptosis. Finally, Galliverti et al. (Galliverti et al., 2018) combined an HPV E7 synthetic long peptide with ultrasmall polymeric nanoparticles to promote the infiltration of CD8+ T cells. Accompanied aggregation of regulatory T cells was not observed, contributing to the enhanced antineoplastic effects of this vaccine.

 Inorganic nanoparticles

Inorganic nanomaterials are composed of inorganic substances with structural units of at least one nanoscale dimension in three-dimensional space (typically 1–100 nm) (Meena et al., 2020). Inorganic nanoparticles can be prepared via the chemical co-precipitation, microemulsion, and pyrolysis methods (Islam et al., 2012). Inorganic nanoparticles are widely used in drug delivery and tumor therapy due to their unique physical and chemical properties, ease of surface modification, and good biocompatibility (Hao et al., 2020). The primary inorganic nanoparticles used in the context of HPV-related diseases are copper oxide, silica, gold, and zinc oxide (Bayda et al., 2018). For example, Yang et al. (2021) developed a novel nanocomposite, polyethyleneimine-modified dendritic mesoporous silica nanoparticle that was loaded with microRNA-125a. This particle showed excellent cellular uptake capacity in the TC-1 cervical cell line. Intratumoral injection synergistically enhanced immune responses and reversed the immunosuppression. Also, it enhanced the infiltration of NKs and CD8+ T cell. In addition, Yi et al. (2016) developed suppression-targeted gold nanoparticles (AuNPs) by loading monodispersed unimer polyion complexes—which consisted of therapeutic siRNA, cyclic Arg-Gly-Asp, and blocking cations—onto AuNPs. These particles not only effectively delivered the HPV E6-targeting siRNAs, but also suppressed xenograft tumors derived from HeLa cells. Finally, Dey et al. (2020) found that chitosan-conjugated copper oxide nanoparticles could inhibit the proliferation of cervical cancer cells and promote the infiltration of CD4+ T cells by triggering humoral IgG-dependent immune responses and activating immune cells to induce cellular immunity.

 Exosomes

Exosomes are small intranuclear particles with a lipid bilayer structure. These extracellular vesicles typically exhibit a cup-shaped morphology and a diameter of approximately 30–150 nm (Raposo and Stoorvogel, 2013). Exosomes can be secreted by various cell types such as tumor cells, lymphocytes, and DCs. They are ubiquitous in body fluids such as blood, urine, and cerebrospinal fluid (Rashed et al., 2017; Wu et al., 2021). Exosomes can facilitate signal transduction between immune cells, thereby activating downstream effector cells. It enables the presentation of tumor-specific antigens to the immune system and inhibits tumor immune escape (Rodrigues et al., 2018). Bioactive components (e.g., drugs, nucleic acids, and proteins) can be encapsulated into exosomes via membrane fusion, electroporation, genetic engineering, and ultrasound loading to achieve targeted drug delivery to specific cells or tissues (Chakravarti et al., 2020). For example, Chen et al. (2018) developed a DC-derived exosome (Dexo) loaded with the E7 (49–57) peptide. Dexo effectively induced the cytolytic activity of CD8+ T cells against TC-1 cervical cancer cells in vitro. Also, it induced the proliferation of CD8+ T cell and the secretion of interferon γ. In addition, the Dexo vaccine promoted E7 antigen-induced immune responses in the splenocytes of immunized mice. Furthermore, Cenik et al. (2022) demonstrated that docetaxel-loaded exosomes (Exo-Doc) could reduce docetaxel dosage and toxicity. At the same time, they induced mitochondrial apoptosis in HeLa cells and increased the metastasis of resistant cells. Finally, Roy et al. (2022) identified adipocyte-derived stem cell exosomes (ACS-exos). Delivery of microRNA-7 to cervical cancer cells with ACS-exos induced downregulation of X-linked inhibitor of apoptosis protein. This study showed that the successful isolation and transfection of exosomes are critical to the use of exosomes for cancer therapy. Moreover, exosome-loaded nucleic acids can be delivered to target cells, leading to altered protein expression.

 Conclusion

In this review, we discuss the application of therapeutic vaccines and adoptive cell therapy to cervical cancer. However, immunotherapy for cervical cancer is marred by challenges such as low immunogenicity, poor targeting, and immunotoxicity. In our summary, we found that the combination of nanotechnology and immunotherapy can eliminate the adverse effects of immunotherapy agents and improve their therapeutic efficacy in cervical cancer. However, these nanotherapeutic agents are still in the preclinical stages of development (Table 2). Due to uncertainty concerning the EPR effect in tumor tissues of different patients, it is unknown whether nanotechnology will improve drug delivery in tumor tissues. Moreover, many challenges remain with respect to translating industrial products to the clinic. Therefore, this review describes a foundation for nanotechnology-mediated cervical cancer immunotherapy. Further research pertaining to the large-scale production, safety, and stability of nanocarrier-loaded immunotherapeutics is needed.

Clinical application of nanotechnology-based therapy for cervical cancer.

Therapeutic agents Therapeutic method Pathways Phase/Status Trial number References
Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, Cisplatin Immunotherapy and chemoradiation JAK/STAT II/Recruitment NCT04580771 (Gutiérrez-Hoya and Soto-Cruz, 2020; Smalley Rumfield et al., 2020)
Pegylated liposomal doxorubicin hydrochloride, Carboplatin Chemotherapy Bcl-2 I-II/Completed NCT00032162 (du Bois et al., 2007; Xia et al., 2020)
Nanoparticle Albumin-Bound Rapamycin Immunotherapy PI3K/Akt/mTOR Early I/Completed NCT02646319 (Jain et al., 2021; Zhang et al., 2021)
BIND-014 (docetaxel nanoparticles for injectable suspension) Chemotherapy PI3K II/Terminated NCT02479178 (Von Hoff et al., 2016; Liu et al., 2019)
Irinotecan liposome, apatinib, PD-1 antibody Chemoradiation, immunotherapy PI3K/Akt/mTOR, PD-1/PD-L1 II/Completed NCT04569916 (Boussen et al., 2010; Guo et al., 2020; He et al., 2021)
Author contributions

XZ and HAL was responsible for the writing of the manuscript, HOL for the editing of the graphs and tables, MF, WX, and YJ for the revision and final review of the manuscript. All authors were involved in the creation and were responsible for the content of the work.

 Funding

This work was supported by the National Natural Science Foundation of China (Grant No. 82003985, 81973712), Jilin Province Science and Technology Development Project in China (Grant No. 20210204013YY, 20200504005YY), Science and Technology Project of Jilin Provincial Department of Education (JJKH20220877KJ).

 Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

 Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

 References Al-Jamal W. T. Al-Jamal K. T. Bomans P. H. Frederik P. M. Kostarelos K. (2008). Functionalized-quantum-dot-liposome hybrids as multimodal nanoparticles for cancer. Small 4, 1406–1415. 10.1002/smll.200701043 Ali R. (2020). Preparation and characterization of dexamethasone polymeric nanoparticle by membrane emulsification method. J. Nanopart. Res 22, 314. 10.1007/s11051-020-05031-1 Aranda‐Rivera A. K. Cruz‐Gregorio A. Briones‐Herrera A. Pedraza‐Chaverri J. (2021). Regulation of autophagy by high‐ and low‐risk human papillomaviruses. Rev. Med. Virol 31, e2169. 10.1002/rmv.2169 Artiga Á. Serrano-Sevilla I. De Matteis L. Mitchell S. G. de la Fuente J. M. (2019). Current status and future perspectives of gold nanoparticle vectors for siRNA delivery. J. Mat. Chem. B 7, 876–896. 10.1039/C8TB02484G Batty C. J. Tiet P. Bachelder E. M. Ainslie K. M. (2019). Drug delivery for cancer immunotherapy and vaccines. Pharm. Nanotechnol 6, 232–244. 10.2174/2211738506666180918122337 Bayda S. Hadla M. Palazzolo S. Riello P. Corona G. Toffoli G. , (2018). Inorganic nanoparticles for cancer therapy: A transition from lab to clinic. Curr. Med. Chem 25, 4269–4303. 10.2174/0929867325666171229141156 Bedell S. L. Goldstein L. S. Goldstein A. R. Goldstein A. T. (2020). Cervical cancer screening: Past, present, and future. Sex. Med. Rev 8, 28–37. 10.1016/j.sxmr.2019.09.005 Bermúdez-Humarán L. G. Cortes-Perez N. G. Le Loir Y. Alcocer-González J. M. Tamez-Guerra R. S. de Oca-Luna R. M. , (2004). An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. J. Med. Microbiol 53, 427–433. 10.1099/jmm.0.05472-0 Boussen H. Cristofanilli M. Zaks T. DeSilvio M. Salazar V. Spector N. (2010). Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. J. Clin. Oncol 28, 3248–3255. 10.1200/JCO.2009.21.8594 Brinkman J. A. Xu X. Kast W. M. (2007). The efficacy of a DNA vaccine containing inserted and replicated regions of the E7 gene for treatment of HPV-16 induced tumors. Vaccine 25, 3437–3444. 10.1016/j.vaccine.2006.12.045 Cassetti M. C. McElhiney S. P. Shahabi V. Pullen J. K. Le Poole I. C. Eiben G. L. , (2004). Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine 22, 520–527. 10.1016/j.vaccine.2003.07.003 Castro K. C. de Costa J. M. Campos M. G. N. (2022). Drug-loaded polymeric nanoparticles: A review. Int. J. Polym. Mater. Polym. Biomaterials 71, 1–13. 10.1080/00914037.2020.1798436 Cenik M. Abas B. I. Kocabiyik B. Demirbolat G. M. Cevik O. (2022). Development of a new drug delivery system from HELA-derived exosomes and the effect of docetaxel-loaded exosomes on mitochondrial apoptosis. J. Pharm. Innov 17, 931–939. 10.1007/s12247-021-09566-1 Chakravarti A. R. Pacelli S. Paul A. (2020). Investigation of human adipose stem cell-derived nanoparticles as a biomimetic carrier for intracellular drug delivery. Nanoscale 12, 24273–24284. 10.1039/D0NR06571D Chen Q. Li Y. Zhou S. Chen D. Zhou M. Chen Q. , (2022). Sequentially sustained release of anticarcinogens for postsurgical chemoimmunotherapy. J. Control. Release 350, 803–814. 10.1016/j.jconrel.2022.09.006 Chen S. Lv M. Fang S. Ye W. Gao Y. Xu Y. (2018). Poly(I:C) enhanced anti-cervical cancer immunities induced by dendritic cells-derived exosomes. Int. J. Biol. Macromol 113, 1182–1187. 10.1016/j.ijbiomac.2018.02.034 Chen W. Huang L. (2008). Induction of cytotoxic T-lymphocytes and antitumor activity by a liposomal lipopeptide vaccine. Mol. Pharm 5, 464–471. 10.1021/mp700126c Choi J. S. Nam K. Park J. Kim J.-B. Lee J.-K. Park J. (2004). Enhanced transfection efficiency of PAMAM dendrimer by surface modification with l-arginine. J. Control. Release 99, 445–456. 10.1016/j.jconrel.2004.07.027 Choi Y. J. Hur S. Y. Kim T.-J. Hong S. R. Lee J. K. Cho C.-H. , (2020). A phase II, prospective, randomized, multicenter, open-label study of GX-188e, an HPV DNA vaccine, in patients with cervical intraepithelial neoplasia 3. Clin. Cancer Res 26, 1616–1623. 10.1158/1078-0432.CCR-19-1513 Cohen P. A. Jhingran A. Oaknin A. Denny L. (2019). Cervical cancer. Lancet 393, 169–182. 10.1016/S0140-6736(18)32470-X Cortes-Perez N. G. Azevedo V. Alcocer-González J. M. Rodriguez-Padilla C. Tamez-Guerra R. S. Corthier G. , (2005). Cell-surface display of E7 antigen from human papillomavirus type-16 in Lactococcus lactis and in Lactobacillus plantarum using a new cell-wall anchor from lactobacilli. J. Drug Target 13, 89–98. 10.1080/10611860400024219 Dai X. Mei Y. Nie J. Bai Z. (2019). Scaling up the manufacturing process of adoptive T cell immunotherapy. Biotechnol. J 14, 1800239. 10.1002/biot.201800239 Dell K. Klein C. Gissmann L. (2008). Comparison of DNA- and mRNA-transfected mouse dendritic cells as potential vaccines against the human papillomavirus type 16 associated oncoprotein E7. Antivir. Ther 13, 495–509. 10.1177/135965350801300409 Dey A. Manna S. Kumar S. Chattopadhyay S. Saha B. Roy S. (2020). Immunostimulatory effect of chitosan conjugated green copper oxide nanoparticles in tumor immunotherapy. Cytokine 127, 154958. 10.1016/j.cyto.2019.154958 Doorbar J. Egawa N. Griffin H. Kranjec C. Murakami I. A. , (2015). Human papillomavirus molecular biology and disease association, Rev. Med. Virol 25107, 2518–23525. 10.1002/rmv.1822 Duan X. Chan C. Lin W. (2019). Nanoparticle-mediated immunogenic cell death enables and potentiates cancer immunotherapy. Angew. Chem. Int. Ed. Engl 58, 670–680. 10.1002/anie.201804882 du Bois A. Pfisterer J. Burchardi N. Loibl S. Huober J. Wimberger N. (2007). Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: A prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut). Gynecologic Oncology 107, 518–525. 10.1016/j.ygyno.2007.08.008 Filipczak N. Pan J. Yalamarty S. S. K. Torchilin V. P. (2020). Recent advancements in liposome technology. Adv. Drug Deliv. Rev 156, 4–22. 10.1016/j.addr.2020.06.022 Fu C. Ma T. Zhou L. Mi Q.-S. Jiang A. (2022). Dendritic cell-based vaccines against cancer: Challenges, advances and future opportunities. Immunol. Invest 2022, 2109486. 10.1080/08820139.2022.2109486 Galliverti G. Tichet M. Domingos-Pereira S. Hauert S. Nardelli-Haefliger D. Swartz M. A. , (2018). Nanoparticle conjugation of human papillomavirus 16 E7-long peptides enhances therapeutic vaccine efficacy against solid tumors in mice. Cancer Immunol. Res 6, 1301–1313. 10.1158/2326-6066.CIR-18-0166 Ghalkhani M. Kaya S. I. Bakirhan N. K. Ozkan Y. Ozkan S. A. (2022). Application of nanomaterials in development of electrochemical sensors and drug delivery systems for anticancer drugs and cancer biomarkers. Crit. Rev. Anal. Chem 52, 481–503. 10.1080/10408347.2020.1808442 Gomez-Gutierrez J. G. Elpek K. G. Montes de Oca-Luna R. Shirwan H. Sam Zhou H. McMasters K. M. (2007). Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice. Cancer Immunol. Immunother 56, 997–1007. 10.1007/s00262-006-0247-2 Guevara M. L. Persano F. Persano S. (2020). Advances in lipid nanoparticles for mRNA-based cancer immunotherapy. Front. Chem 8, 589959. 10.3389/fchem.2020.589959 Guo Q. Sun Y. Kong E. Rao L. Chen J. Wu Q. , (2020). Apatinib combined with chemotherapy or concurrent chemo-brachytherapy in patients with recurrent or advanced cervical cancer: A phase 2, randomized controlled, prospective study. Medicine 99, e19372. 10.1097/MD.0000000000019372 Gutiérrez-Hoya A. Soto-Cruz I. (2020). Role of the JAK/STAT pathway in cervical cancer: Its relationship with HPV E6/E7 oncoproteins. Cells 9, 2297. 10.3390/cells9102297 Haney M. J. Klyachko N. L. Zhao Y. Gupta R. Plotnikova E. G. He Z. , (2015). Exosomes as drug delivery vehicles for Parkinson’s disease therapy. J. Control. Release 207, 18–30. 10.1016/j.jconrel.2015.03.033 Hao Y. Zhou X. Li R. Song Z. Min Y. (2020). Advances of functional nanomaterials for cancer immunotherapeutic applications. Wiley Interdiscip. Rev. Nanomed Nanobiotechnol 12, e1574. 10.1002/wnan.1574 He Z. Zhang M. Wang Y. He Y. Wang H. Chen B. , (2021). Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan/JQ1 for chemo-immunotherapy. Acta Pharmacol. Sin 42, 1516–1523. 10.1038/s41401-020-00570-8 Hsieh C. Kim T. W. Hung C. F. Juang J. Moniz M. Boyd D. A. K. , (2004). Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Vaccine 22, 3993–4001. 10.1016/j.vaccine.2004.03.057 Ibrahim Khalil A. Mpunga T. Wei F. Baussano I. Martel C. Bray F. , (2022). Age‐specific burden of cervical cancer associated with HIV : A global analysis with a focus on sub‐saharan africa. Int. J. Cancer 150, 761–772. 10.1002/ijc.33841 Irvine D. J. Dane E. L. (2020). Enhancing cancer immunotherapy with nanomedicine. Nat. Rev. Immunol 20, 321–334. 10.1038/s41577-019-0269-6 Ishida T. Maeda R. Ichihara M. Irimura K. Kiwada H. (2003). Accelerated clearance of PEGylated liposomes in rats after repeated injections. J. Control. Release 88, 35–42. 10.1016/S0168-3659(02)00462-5 Islam M. S. Kusumoto Y. Kurawaki J. Abdulla-Al-Mamun M. Manaka H. (2012). A comparative study on heat dissipation, morphological and magnetic properties of hyperthermia suitable nanoparticles prepared by co-precipitation and hydrothermal methods. Bull. Mat. Sci 35, 1047–1053. 10.1007/s12034-012-0414-3 Jain P. Kathuria H. Momin M. (2021). Clinical therapies and nano drug delivery systems for urinary bladder cancer. Pharmacol. Ther 226, 107871. 10.1016/j.pharmthera.2021.107871 Jee B. Yadav R. Pankaj S. Shahi S. K. (2021). Immunology of HPV-mediated cervical cancer: Current understanding. Int. Rev. Immunol 40, 359–378. 10.1080/08830185.2020.1811859 Karimi H. Soleimanjahi H. Abdoli A. Banijamali R. S. (2020). Combination therapy using human papillomavirus L1/E6/E7 genes and archaeosome: A nanovaccine confer immuneadjuvanting effects to fight cervical cancer. Sci. Rep 10, 5787. 10.1038/s41598-020-62448-3 Ke X. Ng V. W. L. Ono R. J. Chan J. M. W. Krishnamurthy S. Wang Y. , (2014). Role of non-covalent and covalent interactions in cargo loading capacity and stability of polymeric micelles. J. Control. Release 193, 9–26. 10.1016/j.jconrel.2014.06.061 Kim J. Lee Y. M. Kim H. Park D. Kim J. Kim W. J. (2016). Phenylboronic acid-sugar grafted polymer architecture as a dual stimuli-responsive gene carrier for targeted anti-angiogenic tumor therapy. Biomaterials 75, 102–111. 10.1016/j.biomaterials.2015.10.022 Kranz L. M. Diken M. Haas H. Kreiter S. Loquai C. Reuter K. C. , (2016). Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534, 396–401. 10.1038/nature18300 Kumbhari A. Egelston C. A. Lee P. P. Kim P. S. (2020). Mature dendritic cells may promote high-avidity tuning of vaccine T cell responses. Front. Immunol 11, 584680. 10.3389/fimmu.2020.584680 Lee N. Kim S. I. Lee M. Kim H. S. Kim J. W. Park N. H. , (2019). Bevacizumab efficacy and recurrence pattern of persistent and metastatic cervical cancer. Vivo 33, 863–868. 10.21873/invivo.11551 Li L. Zhang P. Li C. Guo Y. Sun K. (2021). In vitro/vivo antitumor study of modified-chitosan/carboxymethyl chitosan “boosted” charge-reversal nanoformulation. Carbohydr. Polym 269, 118268. 10.1016/j.carbpol.2021.118268 Liontos M. Kyriazoglou A. Dimitriadis I. Dimopoulos M.-A. Bamias A. (2019). Systemic therapy in cervical cancer: 30 years in review. Crit. Rev. Oncol. Hematol 137, 9–17. 10.1016/j.critrevonc.2019.02.009 Liu D.-W. Tsao Y.-P. Kung J. T. Ding Y.-A. Sytwu H.-K. Xiao X. , (2000). Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J. Virol 74, 2888–2894. 10.1128/JVI.74.6.2888-2894.2000 Liu J. J. Ho J. Y. Lee H. W. Baik M. W. Kim O. Choi Y. J. , (2019). Inhibition of phosphatidylinositol 3-kinase (PI3K) signaling synergistically potentiates antitumor efficacy of paclitaxel and overcomes paclitaxel-mediated resistance in cervical cancer. Int. J. Mol. Sci 20, 3383. 10.3390/ijms20143383 Liu Y. Castro Bravo K. M. Liu J. (2021). Targeted liposomal drug delivery: A nanoscience and biophysical perspective. Nanoscale Horiz 6, 78–94. 10.1039/D0NH00605J Lucena A. A. S. Guimarães M. V. M. B. Michelin M. A. Lodi C. T. C. Lima M. I. M. Murta E. F. C. , (2016). Evaluation of T, B and natural killer lymphocyte in the cervical stroma of HIV-positive and negative patients with cervical intraepithelial neoplasia. Immunol. Lett 169, 98–103. 10.1016/j.imlet.2015.10.016 Luiza Ribeiro de Souza A. Priscila Kiill C. Kolenyak dos Santos F. Marielli da Luz G. Rocha e Silva H. Chorilli M. , (2012). Nanotechnology-based drug delivery systems for dermatomycosis treatment. Curr. Nanosci 8, 512–519. 10.2174/157341312801784311 Ma F. Zhang Q. Zheng L. (2015). Interleukin/chitosan (JY) adjuvant enhances the mucosal immunity of human papillomavirus 16 L1 virus-like particles in mice. Biotechnol. Lett 37, 773–777. 10.1007/s10529-014-1739-3 Martin J. D. Cabral H. Stylianopoulos T. Jain R. K. (2020). Improving cancer immunotherapy using nanomedicines: Progress, opportunities and challenges. Nat. Rev. Clin. Oncol 17, 251–266. 10.1038/s41571-019-0308-z Meena J. Gupta A. Ahuja R. Singh M. Bhaskar S. Panda A. K. (2020). Inorganic nanoparticles for natural product delivery: A review. Environ. Chem. Lett 18, 2107–2118. 10.1007/s10311-020-01061-2 Menderes G. Black J. Schwab C. L. Santin A. D. (2016). Immunotherapy and targeted therapy for cervical cancer: An update. Expert Rev. Anticancer Ther 16, 83–98. 10.1586/14737140.2016.1121108 Miles B. Safran H. P. Monk B. J. (2017). Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11–001. Gynecol. Oncol. Res. Pract 4, 10. 10.1186/s40661-017-0047-8 Mishra S. Webster P. Davis M. E. (2004). PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur. J. Cell. Biol 83, 97–111. 10.1078/0171-9335-00363 Nagapoosanam A. Ganesan N. Umapathy D. Moorthy R. Arockiam A. V. (2019). Knockdown of human telomerase reverse transcriptase induces apoptosis in cervical cancer cell line. Indian J. Med. Res 149, 345–353. 10.4103/ijmr.IJMR_1676_16 Öhlschläger P. Pes M. Osen W. Dürst M. Schneider A. Gissmann L. , (2006). An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Vaccine 24, 2880–2893. 10.1016/j.vaccine.2005.12.061 Palantavida S. Guz N. V. Woodworth C. D. Sokolov I. (2013). Ultrabright fluorescent mesoporous silica nanoparticles for prescreening of cervical cancer. Nanomedicine 9, 1255–1262. 10.1016/j.nano.2013.04.011 Pan J. Wan D. Bian Y. Sun H. Zhang C. Jin F. , (2013). Fluorescent hydroxyapatite-loaded biodegradable polymer nanoparticles with folate decoration for targeted imaging. AIChE J 59, 4494–4501. 10.1002/aic.14210 Pandita D. Kumar S. Lather V. (2015). Hybrid poly(lactic-co-glycolic acid) nanoparticles: Design and delivery prospectives. Drug Discov. Today 20, 95–104. 10.1016/j.drudis.2014.09.018 Patel S. K. Billingsley M. M. Frazee C. Han X. Swingle K. L. Qin J. , (2022). Hydroxycholesterol substitution in ionizable lipid nanoparticles for mRNA delivery to T cells. J. Control. Release 347, 521–532. 10.1016/j.jconrel.2022.05.020 Perri S. Greer C. E. Thudium K. Doe B. Legg H. Liu H. , (2003). An alphavirus replicon particle chimera derived from Venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J. Virol 77, 10394–10403. 10.1128/JVI.77.19.10394-10403.2003 Purcell A. W. McCluskey J. Rossjohn J. (2007). More than one reason to rethink the use of peptides in vaccine design. Nat. Rev. Drug Discov 6, 404–414. 10.1038/nrd2224 Raposo G. Stoorvogel W. (2013). Extracellular vesicles: Exosomes, microvesicles, and friends. J. Cell. Biol 200, 373–383. 10.1083/jcb.201211138 Rashed H. M. Bayraktar E. K. Helal G. Abd-Ellah M. Amero P. , (2017). Exosomes: From garbage bins to promising therapeutic targets. Int. J. Mol. Sci 18, 538. 10.3390/ijms18030538 Rodrigues M. Fan J. Lyon C. Wan M. Hu Y. (2018). Role of extracellular vesicles in viral and bacterial infections: Pathogenesis, diagnostics, and therapeutics. Theranostics 8, 2709–2721. 10.7150/thno.20576 Rohaan M. W. Wilgenhof S. Haanen J. B. A. G. (2019). Adoptive cellular therapies: The current landscape. Virchows Arch 474, 449–461. 10.1007/s00428-018-2484-0 Roman L. D. Wilczynski S. Muderspach L. I. Burnett A. F. O’Meara A. Brinkman J. A. , (2007). A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. Gynecol. Oncol 106, 558–566. 10.1016/j.ygyno.2007.05.038 Roy M. Yang Y.-P. Deo S. Daunert S. (2022). Exosome delivery of tumor suppressive microRNA-7 to cervical cancer cells: A novel approach for regulating cervical cancer cell growth (230). Gynecol. Oncol 166, S127–S128. 10.1016/S0090-8258(22)01455-X Sadr S. H. Davaran S. Alizadeh E. Salehi R. Ramazani A. (2018). PLA-based magnetic nanoparticles armed with thermo/pH responsive polymers for combination cancer chemotherapy. J. Drug Deliv. Sci. Technol 45, 240–254. 10.1016/j.jddst.2018.03.019 Sewell D. A. Pan Z. K. Paterson Y. (2008). Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors. Vaccine 26, 5315–5320. 10.1016/j.vaccine.2008.07.036 Shahabi S. Döscher S. Bollhorst T. Treccani L. Maas M. Dringen R. , (2015). Enhancing cellular uptake and doxorubicin delivery of mesoporous silica nanoparticles via surface functionalization: Effects of serum. ACS Appl. Mat. Interfaces 7, 26880–26891. 10.1021/acsami.5b09483 Sheoran S. Arora S. Samsonraj R. Govindaiah P. vuree S. (2022). Lipid-based nanoparticles for treatment of cancer. Heliyon 8, e09403. 10.1016/j.heliyon.2022.e09403 Shi Y. Lammers T. (2019). Combining nanomedicine and immunotherapy. Acc. Chem. Res 52, 1543–1554. 10.1021/acs.accounts.9b00148 Small W. Bacon M. A. Bajaj A. Chuang L. T. Fisher B. J. Harkenrider M. M. , (2017). Cervical cancer: A global health crisis. Cancer 123, 2404–2412. 10.1002/cncr.30667 Smalley Rumfield C. Pellom S. T. Morillon Y. M. II Schlom J. Jochems C. (2020). Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine. J. Immunother. Cancer 8, e000612. 10.1136/jitc-2020-000612 Song H. Su X. Yang K. Niu F. Li J. Song J. , (2015). CD20 antibody-conjugated immunoliposomes for targeted chemotherapy of melanoma cancer initiating cells. J. Biomed. Nanotechnol 11, 1927–1946. 10.1166/jbn.2015.2129 Stark J. M. Tibbitt C. A. Coquet J. M. (2019). The metabolic requirements of Th2 cell differentiation. Front. Immunol 10, 2318. 10.3389/fimmu.2019.02318 Stremersch S. Vandenbroucke R. E. Van Wonterghem E. Hendrix A. De Smedt S. C. Raemdonck K. (2016). Comparing exosome-like vesicles with liposomes for the functional cellular delivery of small RNAs. J. Control. Release 232, 51–61. 10.1016/j.jconrel.2016.04.005 Stuebs F. A. Gass P. Dietl A. K. Schulmeyer C. E. Adler W. Geppert C. , (2021). Human papilloma virus genotype distribution in women with premalignant or malignant lesions of the uterine cervix. Arch. Gynecol. Obstet 304, 751–758. 10.1007/s00404-021-05986-z Tahamtan A. Barati M. Tabarraei A. Reza S. Shirian S. Gorji A. , (2018). Antitumor immunity induced by genetic immunization with chitosan nanoparticle formulated adjuvanted for hpv-16 e7 dna vaccine, Iran J Immunol 12. 10.22034/IJI.2018.39396 Thumrongsiri N. Dana P. Bawab R. Tanyapanyachon P. Treetidnipa C. Saengkrit N. , (2022). Assessment of therapeutic effect of CD20-targeted immunoliposome in primary central nervous system lymphoma. Biomed. Pharmacother 150, 112979. 10.1016/j.biopha.2022.112979 Turinetto M. Valsecchi A. A. Tuninetti V. Scotto G. Borella F. Valabrega G. (2022). Immunotherapy for cervical cancer: Are we ready for prime time? Int. J. Mol. Sci 23, 3559. 10.3390/ijms23073559 Von Hoff D. D. Mita M. M. Ramanathan R. K. Weiss G. J. Mita A. C. LoRusso P. M. , (2016). Phase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced solid tumors. Clin. Cancer Res 22, 3157–3163. 10.1158/1078-0432.CCR-15-2548 Vonsky M. Shabaeva M. Runov A. Lebedeva N. Chowdhury S. Palefsky J. M. , (2019). Carcinogenesis associated with human papillomavirus infection. Mechanisms and potential for immunotherapy. Biochemistry 84, 782–799. 10.1134/S0006297919070095 Wakeham K. Kavanagh K. (2014). The burden of HPV-associated anogenital cancers. Curr. Oncol. Rep 16, 402. 10.1007/s11912-014-0402-4 World Health Organization W. H. O. (2022). World health statistics 2022: Monitoring health for the SDGs, sustainable development goals. https://apps.who.int/iris/handle/10665/356584. Wu S. Li T. Liu W. Huang Y. (2021). Ferroptosis and cancer: Complex relationship and potential application of exosomes. Front. Cell. Dev. Biol 9, 733751. 10.3389/fcell.2021.733751 Xia Y. Xiao M. Zhao M. Xu T. Guo M. Wang C. , (2020). Doxorubicin-loaded functionalized selenium nanoparticles for enhanced antitumor efficacy in cervical carcinoma therapy. Mat. Sci. Eng. C Mat. Biol. Appl 106, 110100. 10.1016/j.msec.2019.110100 Yang L. Li F. Cao Y. Liu Q. Jing G. Niu J. , (2021). Multifunctional silica nanocomposites prime tumoricidal immunity for efficient cancer immunotherapy. J. Nanobiotechnology 19, 328. 10.1186/s12951-021-01073-2 Yang X. Li Y. Li M. Zhang L. Feng L. Zhang N. (2013). Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer. Cancer Lett 334, 338–345. 10.1016/j.canlet.2012.07.002 Ye B. Stary C. M. Gao Q. Wang Q. Zeng Z. Jian Z. , (2017). Genetically modified T-cell-based adoptive immunotherapy in hematological malignancies. J. Immunol. Res 2017, 5210459. 10.1155/2017/5210459 Yeh W.-I. Seay H. R. Newby B. Posgai A. L. Moniz F. B. Michels A. , (2017). Avidity and bystander suppressive capacity of human regulatory T cells expressing de novo autoreactive T-cell receptors in type 1 diabetes. Front. Immunol 8, 1313. 10.3389/fimmu.2017.01313 Yi Y. Kim H. J. Mi P. Zheng M. Takemoto H. Toh K. , (2016). Targeted systemic delivery of siRNA to cervical cancer model using cyclic RGD-installed unimer polyion complex-assembled gold nanoparticles. J. Control. Release 244, 247–256. 10.1016/j.jconrel.2016.08.041 Yin H. Q. Shao G. Gan F. Ye G. (2020). One-step, rapid and green synthesis of multifunctional gold nanoparticles for tumor-targeted imaging and therapy. Nanoscale Res. Lett 15, 29. 10.1186/s11671-019-3232-3 Zeng B. Middelberg A. P. J. Gemiarto A. MacDonald K. Baxter A. G. Talekar M. (2018). Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy. J. Clin. Invest 128, 1971–1984. 10.1172/JCI96791 Zhang J. Hu J. Li W. Zhang C. Su P. Wang Y. , (2021). Rapamycin antagonizes BCRP-mediated drug resistance through the PI3K/Akt/mTOR signaling pathway in mPRα-positive breast cancer. Front. Oncol 11, 608570. 10.3389/fonc.2021.608570 Zhang W. Li S. Li C. Li T. Huang Y. (2022). Remodeling tumor microenvironment with natural products to overcome drug resistance. Front. Immunol 13, 1051998. 10.3389/fimmu.2022.1051998 Zhang Z. Guo Y. Feng S.-S. (2012). Nanoimmunotherapy: Application of nanotechnology for sustained and targeted delivery of antigens to dendritic cells. Nanomedicine 7, 1–4. 10.2217/nnm.11.171